Denis E. Ryono
Bristol-Myers Squibb
66 Papers
764 Citations
Denis E. Ryono is an academic researcher from Bristol-Myers Squibb. The author has contributed to research in topics: Trifluoromethyl & Angiotensin II. The author has an hindex of 22, co-authored 65 publications.
Chat about Author
Papers
Dual Metalloprotease Inhibitors: Mercaptoacetyl-Based Fused Heterocyclic Dipeptide Mimetics as Inhibitors of Angiotensin-Converting Enzyme and Neutral Endopeptidase
Jeffrey A. Robl,Chongqing Sun,Jay Stevenson,Denis E. Ryono,Ligaya M. Simpkins,Maria P. Cimarusti,Tamara Dejneka,William A. Slusarchyk,Sam T. Chao,Leslie Stratton,Raj N. Misra,Mark S. Bednarz,M. M. Asaad,Hong Son Cheung,B.E. Abboa-Offei,Patricia L. Smith,Parker D. Mathers,Maxine Fox,T. R. Schaeffer,and Andrea A. Seymour,Nick C. Trippodo +20 more
TL;DR: A series of 7,6- and 7,5-fused bicyclic thiazepinones and oxazepinones were generated and incorporated as conformationally restricted dipeptide surrogates in mercaptoacyl dipePTides, and compound 1a (BMS-186716) was advanced into clinical development for the treatment of hypertension and congestive heart failure.
201
alpha-Hydroxy phosphinyl-based inhibitors of human renin.
Dinesh V. Patel,Katherine Rielly-Gauvin,Denis E. Ryono,Charles A. Free,W. L. Rogers,Sandra A. Smith,Jack M. DeForrest,R. S. Oehl,Edward W. Petrillo +8 more
TL;DR: The alpha-hydroxy phosphonates represent a promising and structurally novel class of transition state analog inhibitors of human renin and are proposed as a base-line compound for further structure-activity relationship study.
183
Peptidic α-hydroxy phosphinyls C-terminal modification methodology
TL;DR: Compound 4 is a suitable intermediate for making C-terminal mortifications of the transition state mimicking "α-hydroxy-phosphinyl" moiety and its preparmion and application are described in this article.
104
Muraglitazar, a Novel Dual (α/γ) Peroxisome Proliferator–Activated Receptor Activator, Improves Diabetes and Other Metabolic Abnormalities and Preserves β-Cell Function in db/db Mice
Thomas Harrity,Dennis Farrelly,Aaron Tieman,Cuixia Chu,Lori Kunselman,Liqun Gu,Randolph P. Ponticiello,Michael Cap,Fucheng Qu,Chunning Shao,Wei Wang,Hao Zhang,William Fenderson,Chen Sean,Pratik Devasthale,Jeon Yoon T,Ramakrishna Seethala,Wen-Pin Yang,Jimmy Ren,Min Zhou,Denis E. Ryono,Scott A. Biller,Kasim A. Mookhtiar,John R. Wetterau,Richard E. Gregg,Peter T. W. Cheng,Narayanan Hariharan +26 more
TL;DR: The overall conclusions are that in db/db mice, the novel dual PPAR activator exerts potent and efficacious antidiabetic effects, preserves pancreatic insulin content, and improves metabolic abnormalities such as hyperlipidemia, fatty liver, low adiponectin levels, and elevated corticosterone levels.
80
Activated ketone based inhibitors of human renin.
Dinesh V. Patel,Katherine Rielly-Gauvin,Denis E. Ryono,Charles A. Free,Sandra A. Smith,Edward W. Petrillo +5 more
TL;DR: The results collectively suggest that, whereas the trifluoromethyl ketones derive their renin inhibitory potency primarily from their ability to become hydrated, this is not a critical feature for the activity of alpha-dicarbonyl-based inhibitors.
79